Plaintiffs v AstraZeneca

WIN AN iPOD TOUCH!*
Sign Up For Our FREE Weekly Alerts




 
General Alerts
General Alerts include all recent cases, recalls and complaints.
Automotive Alerts
Make sure YOUR car has not been recalled and you are safe.
Family Alerts
Keep track of recalls and cases that affect you and your children.
Health and Medical Alerts
Are the prescription drugs and medical devices YOU use safe?
Consumer Alerts
Get notified about recalled products around your home.
Environmental Alerts
Keep up with pollution and contamination that may affect you.
Financial Alerts
Keep an eye on your investments.
 
 

Appeals Court Denies AstraZeneca in AWP Case

Case ID: 5588
Amount At Issue: $12,900,000.00
Category: Miscellaneous
 
Last Update: 09/28/2009
Country:
 

The First Circuit of the United States Court of Appeals upheld an earlier ruling of the trial court in a Massachusetts case against AstraZeneca (NYSE: AZN - News) that concluded the drug giant engaged in unfair and deceptive trade practices by inflating the price of prescription drug Zoladex, clearing the way for a national class-action lawsuit to move forward.

The 98-page ruling affirms a judgment of $12.9 million against the company for violating the Massachusetts Consumer Protection Act.

The ruling also clears the way for a national class-action lawsuit originally certified by U.S. District Court Judge Patti Saris on Sept. 29, 2008, which was temporarily stayed until the resolution of AstraZeneca's appeal.

The case was originally filed Sept. 2, 2002 and claimed AstraZeneca grossly inflated the price of Zoladex, primarily used to treat prostate cancer, by misstating the Average Wholesale Price (AWP) of these drugs in industry publications. The published AWP sets the price that consumers, insurance companies and other third-party payors pay for the drug, and the lawsuit contends that consumers and third-party payors often paid more than market value because of the drug company's deceptive AWP reporting.

Steve Berman, managing partner of Hagens Berman Sobol Shapiro and lead attorney said he is looking forward to extending the state ruling and using it to represent consumers and other third-party payors in the national class.

The ruling the court upheld affects patients and insurers who made co-payments and reimbursements for Zoladex from December 1997 to 2003.

The Court also rejected the defense that third-party payors knew of the spreads and thus were not deceived.

Berman indicated the class plaintiffs will seek a trial of the nationwide case next year.

CONTACT:

Steve Berman (206) 623-7292 Mark Firmani (206) 443-9357
Hagens Berman Sobol Shapiro Firmani + Associates
Steve@hbsslaw.com Mark@firmani.com

Browse Class Actions in the following categories.

 
GO
 
 
 
Class Action Lawsuit Center || Product Recall Center || Consumer Complaint Center || About LawCash || Privacy Policy || Terms & Conditions
LawCash® is a service of skyMedia, llc © 2000 - 2010 Copyright. All rights reserved skyMedia, llc.